Viking Therapeutics
VKTX
197 hedge funds and large institutions have $1.45B invested in Viking Therapeutics in 2023 Q4 according to their latest regulatory filings, with 48 funds opening new positions, 61 increasing their positions, 54 reducing their positions, and 30 closing their positions.
124% more call options, than puts
Call options by funds: $65.7M | Put options by funds: $29.3M
70% more capital invested
Capital invested by funds: $854M → $1.45B (+$596M)
60% more first-time investments, than exits
New positions opened: 48 | Existing positions closed: 30
13% more repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 54
10% more funds holding
Funds holding: 179 → 197 (+18)
0.78% more ownership
Funds ownership: 77.13% → 77.91% (+0.78%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$27.9M |
| 2 |
Pictet Asset Management
Carouge,
Switzerland
|
+$8.94M |
| 3 |
Massachusetts Financial Services
Boston,
Massachusetts
|
+$8.67M |
| 4 |
Viking Global Investors
Stamford,
Connecticut
|
+$7.48M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$7.08M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
-$22.1M |
| 2 |
Millennium Management
New York
|
-$15.6M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$9.51M |
| 4 |
State Street
Boston,
Massachusetts
|
-$8.87M |
| 5 |
Group One Trading
Chicago,
Illinois
|
-$6.6M |
VKTX Hedge Fund Activity: Q4 2023 in Review
197 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Viking Therapeutics (VKTX) for Q4 2023, worth a combined $1.45B — up 70% from $854M a quarter earlier.
Buyers outnumbered sellers: 48 funds opened new VKTX positions and 30 closed out — a net gain of 18 holders — while 61 added to existing stakes and 54 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $27.9M. The largest seller was Boxer Capital, exiting entirely with an estimated $22.1M sold.
- 197 institutional investors held Viking Therapeutics (VKTX) as of Q4 2023, up from 179 in Q3 2023.
- Funds reported $1.45B of Viking Therapeutics stock for Q4 2023, up 70% quarter-over-quarter.
- 48 funds opened new Viking Therapeutics positions in Q4 2023 and 30 closed out, a net change of +18 holders.
- The largest Viking Therapeutics buyer in Q4 2023 was Morgan Stanley, an estimated $27.9M added.
- The largest Viking Therapeutics seller in Q4 2023 was Boxer Capital, an estimated $22.1M sold.
Based on aggregated 13F filings for Q4 2023.